Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.
Open original sourceLoading market dashboard
CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.
Open original source